A federal award of up to $41 million from the Advanced Research Projects Agency for Health (ARPA-H) is funding a four-year effort to build a national clinical trial platform aimed at finding treatments that could prevent or slow Alzheimer's disease. The project, titled "Platform Trial for Biomarker-Guided Alzheimer's Disease Prevention," is led by The McCance Center for Brain Health at Mass General Brigham, with researchers from the University of California San Diego joining as collaborators.
The central idea is to test several treatments within one shared trial infrastructure instead of designing a separate study for each candidate. The platform is expected to evaluate five to 10 treatment regimens, combining natural products, repurposed FDA-approved drugs and other potential therapies. Approaches that do not show enough promise can be dropped, while the stronger ones move forward, with the aim of reducing duplicated work and shortening the time needed to decide which therapies deserve larger studies.
Rather than waiting for changes in memory or thinking, the researchers plan to rely on blood-based biomarkers. The primary marker is p-tau217, a form of the tau protein that can be measured in blood and is associated with Alzheimer's-related changes in the brain. Other blood markers linked to amyloid plaques, inflammation and nerve cell damage will also be examined. Participants will have no cognitive impairment or mild impairment, but biomarkers suggesting early Alzheimer's-related changes. Studying people earlier in the disease process is meant to test whether treatments can act before extensive brain damage occurs.
The UC San Diego team, including Judy Pa of the Alzheimer's Disease Cooperative Study (ADCS), will coordinate participating clinical trial sites and help standardize study protocols, data collection and the handling of blood samples. The project is designed to eventually operate across 20 sites. By the end of the four years, investigators aim to have biomarker and safety data for five to 10 treatment regimens and to identify the strongest candidates for larger, confirmatory trials. The researchers also hope the infrastructure will remain useful for evaluating new candidates after the initial funding ends.